Albumedix Ltd., a company specializing in recombinant human albumin for advanced therapies, completed the expansion of its commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art labs at its UK-based campus in Nottingham.
 
“Biopharmaceuticals has for a long time been a truly innovative corner of our industry; over the past 5-10 years we have experienced the incredible speed by which cellular and gene therapies have moved from jaw-dropping science to transformative therapies,” said Albumedix Chief Executive Officer Jonas Skjødt Møller. “We are proud to play our part and remain committed to enable the global development of safe, stable and scalable therapies”.
 
The company now officially manufactures out of the new four-story manufacturing extension, significantly increasing its annual product capacity.
 
The expanded manufacturing facility will service increasing demand from a growing portfolio of clients actively relying on Albumedix’ products and technologies in their development of cell therapies, gene therapies, vaccines, medical devices, diagnostics, protein and peptide therapeutics.
 
The new Technology Centre has now been established with facilities classified at BSL2 and BSL2+ to support customers in the advanced therapy field.